Biomarkers have been the mainstay in the diagnosis and follow-up of patients with neuroendocrine tumors (NETs) over the last few decades. In the beginning, secretory products from a variety of subtypes of NETs were regarded as biomarkers to follow during diagnosis and treatment: serotonin for small intestinal (SI) NETs, and gastrin and insulin for pancreatic NETs. However, it became evident that a large number of NETs were so-called nonfunctioning tumors without secreting substances that caused hormone-related symptoms. Therefore, it was necessary to develop so-called “general tumor markers.” The most important ones so far have been chromogranin A and neuron-specific enolase (NSE). Chromogranin A is the most important general biomarker for most NETs with a sensitivity and specificity somewhere between 60 and 90%. NSE has been a relevant biomarker for patients with high-grade tumors, particularly lung and gastrointestinal tract tumors. Serotonin and the breakdown product urinary 5-hydroxyindoleacetic acid (U-5-HIAA) is still an important marker for diagnosing and follow-up of SI NETs. Recently, 5-HIAA in plasma has been analyzed by high-performance liquid chromatography and fluorometric detection and has shown good agreement with U-5-HIAA analysis. In the future, we will see new tests including circulating tumor cells, circulating DNA and mRNA. Recently, a NET test has been developed analyzing gene transcripts in circulating blood. Preliminary data indicate high sensitivity and specificity for NETs. However, its precise role has to be validated in prospective randomized controlled trials which are ongoing right now.

Keywords:
Biomarkers, Chromogranin A, Urinary 5-hydroxyindoleacetic acid, Neuroendocrine tumor test
1.
Meijer WG, Kema IP, Volmer M, Willemse PH, de Vries EG: Discriminating capacity of indole markers in the diagnosis of carcinoid tumors. Clin Chem 2000;46:1588-1596.
2.
Feldman JM: Urinary serotonin in the diagnosis of carcinoid tumors. Clin Chem 1986;32:840-844.
3.
Feldman JM, O'Dorisio TM: Role of neuropeptides and serotonin in the diagnosis of carcinoid tumors. Am J Med 1986;81:41-48.
4.
Janson ET, Holmberg L, Stridsberg M, et al: Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol 1997;8:685-690.
5.
Adaway JE, Dobson R, Walsh J, et al: Serum and plasma 5-hydroxyindoleacetic acid as an alternative to 24-h urine 5-hydroxyindoleacetic acid measurement. Ann Clin Biochem 2016;53:554-560.
6.
Tohmola N, Itkonen O, Sane T, et al: Analytical and preanalytical validation of a new mass spectrometric serum 5-hydroxyindoleacetic acid assay as neuroendocrine tumor marker. Clin Chim Acta 2014;428:38-43.
7.
Tellez MR, Mamikunian G, O'Dorisio TM, Vinik AI, Woltering EA: A single fasting plasma 5-HIAA value correlates with 24-h urinary 5-HIAA values and other biomarkers in midgut neuroendocrine tumors (NETs). Pancreas 2013;42:405-410.
8.
Turner GB, Johnston BT, McCance DR, et al: Circulating markers of prognosis and response to treatment in patients with midgut carcinoid tumours. Gut 2006;55:1586-1591.
9.
van der Horst-Schrivers AN, Post WJ, Kema IP, et al: Persistent low urinary excretion of 5-HIAA is a marker for favourable survival during follow-up in patients with disseminated midgut carcinoid tumours. Eur J Cancer 2007;43:2651-2657.
10.
Formica V, Wotherspoon A, Cunningham D, et al: The prognostic role of WHO classification, urinary 5-hydroxyindoleacetic acid and liver function tests in metastatic neuroendocrine carcinomas of the gastroenteropancreatic tract. Br J Cancer 2007;96:1178-1182.
11.
Kissinger PT, Felice LJ, Riggin RM, Pachla LA, Wenke DC: Electrochemical detection of selected organic components in the eluate from high-performance liquid-chromatography. Clin Chem 1974;20:992-997.
12.
Mailman RB, Kilts CD: Analytical considerations for quantitative determination of serotonin and its metabolically related products in biological matrices. Clin Chem 1985;31:1849-1854.
13.
Kema IP, de Vries EG, Muskiet FA: Clinical chemistry of serotonin and metabolites. J Chromatogr B Biomed Sci Appl 2000;747:33-48.
14.
Kroll CA, Magera MJ, Helgeson JK, Matern D, Rinaldo P: Liquid chromatographic-tandem mass spectrometric method for the determination of 5-hydroxyindole-3-acetic acid in urine. Clin Chem 2002;48:2049-2051.
15.
Kema IP, Meijer WG, Meiborg G, Ooms B, Willemse PH, de Vries EG: Profiling of tryptophan-related plasma indoles in patients with carcinoid tumors by automated, on-line, solid-phase extraction and HPLC with fluorescence detection. Clin Chem 2001;47:1811-1820.
16.
Mulder EJ, Oosterloo-Duinkerken A, Anderson GM, De Vries EG, Minderaa RB, Kema IP: Automated on-line solid-phase extraction coupled with HPLC for measurement of 5-hydroxyindole-3-acetic acid in urine. Clin Chem 2005;51:1698-1703.
17.
Cleare AJ, Keating J, Ealing J, Sherwood RA: A case of coeliac disease detected via raised 5-hydroxytryptamine and 5-hydroxyindoleacetic acid. Ann Clin Biochem 1997;34:440-441.
18.
Bearcroft CP, Perrett D, Farthing MJ: Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: a pilot study. Gut 1998;42:42-46.
19.
Nuttall KL, Pingree SS: The incidence of elevations in urine 5-hydroxyindoleacetic acid. Ann Clin Lab Sci 1998;28:167-174.
20.
Kema IP, Schellings AM, Meiborg G, Hoppenbrouwers CJ, Muskiet FA: Influence of a serotonin- and dopamine-rich diet on platelet serotonin content and urinary excretion of biogenic amines and their metabolites. Clin Chem 1992;38:1730-1736.
21.
Mashige F, Matsushima Y, Kanazawa H, et al: Acidic catecholamine metabolites and 5-hydroxyindoleacetic acid in urine: the influence of diet. Ann Clin Biochem 1996;33:43-49.
22.
Zandee WT, Kamp K, van Adrichem RC, Feelders RA, de Herder WW: Limited value for urinary 5-HIAA excretion as prognostic marker in gastrointestinal neuroendocrine tumours. Eur J Endocrinol 2016;175:361-366.
23.
Service FJ: Hypoglycemic disorders. N Engl J Med 1995;332:1144-1152.
24.
Hirshberg B, Skarulis MC, Pucino F, Csako G, Brennan R, Gorden P: Repaglinide-induced factitious hypoglycemia. J Clin Endocrinol Metab 2001;86:475-477.
25.
de Herder WW, Niederle B, Scoazec JY, et al: Well-differentiated pancreatic tumor/carcinoma: insulinoma. Neuroendocrinology 2006;84:183-188.
26.
Service FJ, Dale AJ, Elveback LR, Jiang NS: Insulinoma: clinical and diagnostic features of 60 consecutive cases. Mayo Clin Proc 1976;51:417-429.
27.
Hirshberg B, Livi A, Bartlett DL, et al: Forty-eight-hour fast: the diagnostic test for insulinoma. J Clin Endocrinol Metab 2000;85:3222-3226.
28.
Service FJ, Natt N: The prolonged fast. J Clin Endocrinol Metab 2000;85:3973-3974.
29.
Grant CS: Insulinoma. Best Pract Res Clin Gastroenterol 2005;19:783-798.
30.
Berna MJ, Hoffmann KM, Serrano J, Gibril F, Jensen RT: Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2,229 cases from the literature. Medicine (Baltimore) 2006;85:295-330.
31.
Frucht H, Howard JM, Slaff JI, et al: Secretin and calcium provocative tests in the Zollinger-Ellison syndrome. A prospective study. Ann Intern Med 1989;111:713-722.
32.
Frucht H, Howard JM, Stark HA, et al: Prospective study of the standard meal provocative test in Zollinger-Ellison syndrome. Am J Med 1989;87:528-536.
33.
Berna MJ, Hoffmann KM, Long SH, Serrano J, Gibril F, Jensen RT: Serum gastrin in Zollinger-Ellison syndrome: II. Prospective study of gastrin provocative testing in 293 patients from the National Institutes of Health and comparison with 537 cases from the literature. Evaluation of diagnostic criteria, proposal of new criteria, and correlations with clinical and tumoral features. Medicine (Baltimore) 2006;85:331-364.
34.
Jensen RT, Niederle B, Mitry E, et al: Gastrinoma (duodenal and pancreatic). Neuroendocrinology 2006;84:173-182.
35.
Shah P, Singh MH, Yang YX, Metz DC: Hypochlorhydria and achlorhydria are associated with false-positive secretin stimulation testing for Zollinger-Ellison syndrome. Pancreas 2013;42:932-936.
36.
Deftos LJ: Chromogranin A: its role in endocrine function and as an endocrine and neuroendocrine tumor marker. Endocr Rev 1991;12:181-187.
37.
Rindi G, Kloppel G: Endocrine tumors of the gut and pancreas tumor biology and classification. Neuroendocrinology 2004;80(suppl 1):12-15.
38.
O'Connor DT, Deftos LJ: Secretion of chromogranin A by peptide-producing endocrine neoplasms. N Engl J Med 1986;314:1145-1151.
39.
Nobels FR, Kwekkeboom DJ, Coopmans W, et al: Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab 1997;82:2622-2628.
40.
Taupenot L, Harper KL, O'Connor DT: The chromogranin-secretogranin family. N Engl J Med 2003;348:1134-1149.
41.
Goebel SU, Serrano J, Yu F, Gibril F, Venzon DJ, Jensen RT: Prospective study of the value of serum chromogranin A or serum gastrin levels in the assessment of the presence, extent, or growth of gastrinomas. Cancer 1999;85:1470-1483.
42.
Baudin E, Gigliotti A, Ducreux M, et al: Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours. Br J Cancer 1998;78:1102-1107.
43.
Sanduleanu S, De Bruine A, Stridsberg M, et al: Serum chromogranin A as a screening test for gastric enterochromaffin-like cell hyperplasia during acid-suppressive therapy. Eur J Clin Invest 2001;31:802-811.
44.
Sobol RE, Memoli V, Deftos LJ: Hormone-negative, chromogranin A-positive endocrine tumors. N Engl J Med 1989;320:444-447.
45.
O'Connor DT, Pandlan MR, Carlton E, Cervenka JH, Hslao RJ: Rapid radioimmunoassay of circulating chromogranin A: in vitro stability, exploration of the neuroendocrine character of neoplasia, and assessment of the effects of organ failure. Clin Chem 1989;35:1631-1637.
46.
Eriksson B, Arnberg H, Oberg K, et al: A polyclonal antiserum against chromogranin A and B - a new sensitive marker for neuroendocrine tumours. Acta Endocrinol (Copenh) 1990;122:145-155.
47.
Zatelli MC, Torta M, Leon A, et al: Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study. Endocr Relat Cancer 2007;14:473-482.
48.
Stridsberg M, Eriksson B, Oberg K, Janson ET: A comparison between three commercial kits for chromogranin A measurements. J Endocrinol 2003;177:337-341.
49.
Turner NC, Strauss SJ, Sarker D, et al: Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. Br J Cancer 2010;102:1106-1112.
50.
Bergestuen DS, Aabakken L, Holm K, Vatn M, Thiis-Evensen E: Small intestinal neuroendocrine tumors: prognostic factors and survival. Scand J Gastroenterol 2009;44:1084-1091.
51.
Hsiao RJ, Mezger MS, O'Connor DT: Chromogranin A in uremia: progressive retention of immunoreactive fragments. Kidney Int 1990;37:955-964.
52.
Stridsberg M, Husebye ES: Chromogranin A and chromogranin B are sensitive circulating markers for phaeochromocytoma. Eur J Endocrinol 1997;136:67-73.
53.
Rozansky DJ, Wu H, Tang K, Parmer RJ, O'Connor DT: Glucocorticoid activation of chromogranin A gene expression. Identification and characterization of a novel glucocorticoid response element. J Clin Invest 1994;94:2357-2368.
54.
Giovanella L, La Rosa S, Ceriani L, Uccella S, Erba P, Garancini S: Chromogranin-A as a serum marker for neuroendocrine tumors: comparison with neuron-specific enolase and correlation with immunohistochemical findings. Int J Biol Markers 1999;14:160-166.
55.
O'Toole D: Current trend: endocrine tumors of the stomach, small bowel, colon and rectum. Gastroenterol Clin Biol 2006;30:276-291.
56.
D'Adda T, Corleto V, Pilato FP, et al: Quantitative ultrastructure of endocrine cells of oxyntic mucosa in Zollinger-Ellison syndrome. Correspondence with light microscopic findings. Gastroenterology 1990;99:17-26.
57.
Stabile BE, Howard TJ, Passaro E Jr, O'Connor DT: Source of plasma chromogranin A elevation in gastrinoma patients. Arch Surg 1990;125:451-453.
58.
Levinson SS, Miller JJ: Towards a better understanding of heterophile (and the like) antibody interference with modern immunoassays. Clin Chim Acta 2002;325:1-15.
59.
Giovanella L, Ceriani L, Lumastro C, Ghelfo A: False-positive serum chromogranin A assay due to heterophile antibody interference. Clin Chim Acta 2007;379:171-172.
60.
Stridsberg M: Measurements of chromogranins and chromogranin-related peptides by immunological methods. Adv Exp Med Biol 2000;482:319-327.
61.
Laslop A, Doblinger A, Weiss U: Proteolytic processing of chromogranins. Adv Exp Med Biol 2000;482:155-166.
62.
Portela-Gomes GM, Stridsberg M: Selective processing of chromogranin A in the different islet cells in human pancreas. J Histochem Cytochem 2001;49:483-490.
63.
Iacangelo AL, Eiden LE: Chromogranin A: current status as a precursor for bioactive peptides and a granulogenic/sorting factor in the regulated secretory pathway. Regul Pept 1995;58:65-88.
64.
O'Connor DT, Bernstein KN: Radioimmunoassay of chromogranin A in plasma as a measure of exocytotic sympathoadrenal activity in normal subjects and patients with pheochromocytoma. N Engl J Med 1984;311:764-770.
65.
Stridsberg M, Oberg K, Li Q, Engstrom U, Lundqvist G: Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. J Endocrinol 1995;144:49-59.
66.
Leon A, Torta M, Dittadi R, et al: Comparison between two methods in the determination of circulating chromogranin A in neuroendocrine tumors (NETs): results of a prospective multicenter observational study. Int J Biol Markers 2005;20:156-168.
67.
Verderio P, Dittadi R, Marubini E, et al: An Italian program of External Quality Control for chromogranin A (CgA) assay: performance evaluation of CgA determination. Clin Chem Lab Med 2007;45:1244-1250.
68.
Lindholm DP, Öberg K: Biomarkers and molecular imaging in gastroenteropancreatic neuroendocrine tumors. Horm Metab Res 2011;43:832-837.
69.
Yao JC, Pavel M, Phan AT, et al: Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. J Clin Endocrinol Metab 2011;96:3741-3749.
70.
van Adrichem RC, Kamp K, Vandamme T, Peeters M, Feelders RA, de Herder WW: Serum neuron-specific enolase level is an independent predictor of overall survival in patients with gastroenteropancreatic neuroendocrine tumors. Ann Oncol 2016;27:746-747.
71.
Korse CM, Taal BG, Vincent A, et al: Choice of tumour markers in patients with neuroendocrine tumours is dependent on the histological grade. A marker study of Chromogranin A, Neuron specific enolase, Progastrin-releasing peptide and cytokeratin fragments. Eur J Cancer 2012;48:662-671.
72.
Sherman SK, Maxwell JE, O'Dorisio MS, O'Dorisio TM, Howe JR: Pancreastatin predicts survival in neuroendocrine tumors. Ann Surg Oncol 2014;21:2971-2980.
73.
Mamikunian P, Ardill JE, O'Dorisio TM, et al: Validation of neurokinin a assays in the United States and Europe. Pancreas 2011;40:1000-1005.
74.
Ardill JE, O'Dorisio TM: Circulating biomarkers in neuroendocrine tumors of the enteropancreatic tract: application to diagnosis, monitoring disease, and as prognostic indicators. Endocrinol Metab Clin North Am 2010;39:777-790.
75.
Ferone D, Albertelli M: Ectopic Cushing and other paraneoplastic syndromes in thoracic neuroendocrine tumors. Thorac Surg Clin 2014;24:277-283.
76.
Bhattacharyya S, Toumpanakis C, Caplin ME, Davar J: Usefulness of N-terminal pro-brain natriuretic peptide as a biomarker of the presence of carcinoid heart disease. Am J Cardiol 2008;102:938-942.
77.
Modlin IM, Frilling A, Salem RR, et al: Blood measurement of neuroendocrine gene transcripts defines the effectiveness of operative resection and ablation strategies. Surgery 2016;159:336-347.
78.
Cwikla JB, Bodei L, Kolasinska-Cwikla A, Sankowski A, Modlin IM, Kidd M: Circulating transcript analysis (NETest) in GEP-NETs treated with somatostatin analogs defines therapy. J Clin Endocrinol Metab 2015;100:E1437-E1445.
79.
Modlin IM, Kidd M, Bodei L, Drozdov I, Aslanian H: The clinical utility of a novel blood-based multi-transcriptome assay for the diagnosis of neuroendocrine tumors of the gastrointestinal tract. Am J Gastroenterol 2015;110:1223-1232.
80.
Khan MS, Kirkwood AA, Tsigani T, et al: Early changes in circulating tumor cells are associated with response and survival following treatment of metastatic neuroendocrine neoplasms. Clin Cancer Res 2016;22:79-85.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.